Last reviewed · How we verify

NCT06204679

Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir

Completed Phase 1 Last updated 19 September 2024
What this trial tests

Phase 1 trial testing Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions in Healthy Volunteer Study in 42 participants. Completed in 25 August 2024.

Timeline
14 December 2023
Primary endpoint
25 August 2024
25 August 2024

Quick facts

Lead sponsorAtea Pharmaceuticals, Inc.
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment42
Start date14 December 2023
Primary completion25 August 2024
Estimated completion25 August 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Atea Pharmaceuticals, Inc. — full company profile →

Who can join

Adults 18 to 65, any sex, with Healthy Volunteer Study. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will assess comparative bioavailability and effect of food on a prototype fixed-dose combination (FDC) of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in healthy subjects

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Clinical Evaluation of Potential Interaction Between Bemnifosbuvir and Ruzasvir With an Assessment of Food Effect: Results of a Phase 1 Study in Healthy Participants.
    Zhou XJ, Morelli G, Montrond M, Lynch S, et al · · 2025 · cited 2× · PMID 40272375 · DOI 10.1002/cpdd.1540

Verify or expand the search:

Other recruiting trials for Healthy Volunteer Study

Currently open trials in the same condition.

Other Atea Pharmaceuticals, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06204679.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing